ステージ IIB ~ IIIB (N2) の切除可能な NSCLC 患者を対象に、術前化学療法とデュルバルマブの併用後にアジュバント デュルバルマブを追加する利点を評価する国際多施設共同非盲検ランダム化第 III 相試験 (ADOPT-lung)
ADOPT-lung is an international, multicentre, open-label randomised phase III trial. Protocol treatment consists of 3-4 cycles of neoadjuvant durvalumab in combination with platinum-based doublet chemotherapy, followed by surgery. Patients with R0 and R1 only resection will be randomised to receive either adjuvant durvalumab for 12 cycles (experimental arm) or observation (control arm). The primary objective of the study is to determine whether additional adjuvant immunotherapy with durvalumab after neoadjuvant chemo-immunotherapy has an effect on disease-free survival (DFS) in patients who do not achieve complete pathological response (pCR) as per local assessment according to the IASLC recommendations.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Heidi Roschitzki, PhD
- 電話番号:+41 31 511 94 00
- メール:heidi.roschitzki@etop.ibcsg.org
研究連絡先のバックアップ
- 名前:Susanne Roux
- 電話番号:+41 31 511 94 00
- メール:ADOPT-lung@etop.ibcsg.org
研究場所
-
-
-
Dublin、アイルランド
- 募集
- Beaumont Hospital
-
コンタクト:
- Jarushka Naidoo
- メール:jarushkanaidoo@beaumont.ie
-
Dublin、アイルランド
- 募集
- St James's Hospital
-
コンタクト:
- Patrick Forde
- メール:pforde1@jhmi.edu
-
-
-
-
-
Cardiff、イギリス
- 募集
- Velindre University NHS Trust
-
コンタクト:
- Paul Shaw
-
Glasgow、イギリス
- まだ募集していません
- Beatson West of Scotland Cancer Centre NHS Greater Glasgow and Clyde
-
コンタクト:
- Nicola Steele
-
London、イギリス
- 募集
- Barts Health NHS Trust
-
コンタクト:
- Adam Januszewski
- メール:adam.januszewski@nhs.net
-
London、イギリス
- まだ募集していません
- Royal Marsden Hospital (Chelsea)
-
コンタクト:
- Sanjay Popat
- メール:sanjay.popat@rmh.nhs.uk
-
London、イギリス
- まだ募集していません
- Royal Marsden Hospital (Sutton)
-
コンタクト:
- Sanjay Popat
- メール:sanjay.popat@rmh.nhs.uk
-
Maidstone、イギリス
- 募集
- Maidstone and Tunbridge Wells NHS Trust
-
コンタクト:
- Riyaz Shah
- メール:riyaz.shah@nhs.net
-
Manchester、イギリス
- 募集
- Wythenshawe Hospital, Manchester University NHS Foundation Trust
-
コンタクト:
- Igor Randulfe
- メール:yvonne.summers@nhs.net
-
-
-
-
-
Alessandria、イタリア
- まだ募集していません
- SS Antonio e Biagio e Cesare Arrigo Hospital
-
コンタクト:
- Pier Luigi Piovano
- メール:plpiovano@ospedale.al.it
-
Padova、イタリア
- 募集
- Istituto Oncologico Veneto
-
コンタクト:
- Laura Bonnano
- メール:laura.bonanno@iov.veneto.it
-
Perugia、イタリア
- まだ募集していません
- Perugia Hospital
-
コンタクト:
- Giulio Metro
- メール:giulio.metro@ospedale.perugia.it
-
Rome、イタリア
- 募集
- Istituto Nazionale Tumori "Regina Elena"
-
コンタクト:
- Landi Lorenza
- メール:lorenza.landi@ifo.it
-
Siena、イタリア
- まだ募集していません
- AOUS Policlinico Le Scotte
-
コンタクト:
- Michele Maio
- メール:mmaiocro@gmail.com
-
Verona、イタリア
- 募集
- Universita di Verona - Department of Medicine
-
コンタクト:
- Lorenzo Belluomini
- メール:lorenzo.belluomini@univr.it
-
-
-
-
-
Talinn、エストニア
- 募集
- North Estonia Medical Centre Foundation
-
コンタクト:
- Kersti Oselin
- メール:Kersti.Oselin@regionaalhaigla.ee
-
-
-
-
-
Amsterdam、オランダ
- 募集
- NKI
-
コンタクト:
- Willemijn Theelen
- メール:w.theelen@nki.nl
-
Utrecht、オランダ
- 募集
- UMCU
-
コンタクト:
- W.K. de Jong
- メール:w.k.dejong-9@umcutrecht.nl
-
-
-
-
New South Wales
-
Camperdown、New South Wales、オーストラリア
- まだ募集していません
- Chris O'Brien Lifehouse
-
コンタクト:
- Malinda Itchins
-
Penrith、New South Wales、オーストラリア
- 募集
- Nepean Hospital
-
コンタクト:
- Deme Karikios
-
St Leonards、New South Wales、オーストラリア
- 募集
- Royal North Shore Hospital
-
コンタクト:
- Malinda Itchins
-
-
Queensland
-
Woolloongabba、Queensland、オーストラリア
- まだ募集していません
- Princess Alexandra Hospital
-
コンタクト:
- Kenneth O'Bryne
-
-
South Australia
-
Bedford Park、South Australia、オーストラリア
- まだ募集していません
- Flinders Medical Centre
-
コンタクト:
- Chris Karapetis
-
-
Tasmania
-
Hobart、Tasmania、オーストラリア
- まだ募集していません
- Royal Hobart Hospital
-
コンタクト:
- Rebecca Tay
-
-
Victoria
-
Box Hill、Victoria、オーストラリア
- 募集
- Eastern Health
-
コンタクト:
- Phillip Parente
-
Melbourne、Victoria、オーストラリア
- 募集
- Alfred Hospital
-
コンタクト:
- Maggie Moore
-
Parkville、Victoria、オーストラリア
- 募集
- Peter MacCallum Cancer Centre
-
コンタクト:
- Benjamin Solomon
-
-
Western Australia
-
Nedlands、Western Australia、オーストラリア
- まだ募集していません
- Sir Charles Gairdner Hospital
-
コンタクト:
- Samantha Bowyer
-
-
-
-
-
Vienna、オーストリア
- 募集
- Wien AKH
-
コンタクト:
- Clemens Aigner
- メール:clemens.aigner@meduniwien.ac.at
-
-
-
-
-
Baden、スイス
- まだ募集していません
- Kantonsspital Baden
-
コンタクト:
- Sacha Rothschild
- メール:sacha.rothschild@ksb.ch
-
Basel、スイス
- 募集
- Universitätsspital Basel
-
コンタクト:
- David König
- メール:david.koenig@usb.ch
-
Bellinzona、スイス
- まだ募集していません
- Eoc - Iosi
-
コンタクト:
- Martina Imbimbo
- メール:martina.imbimbo@eoc.ch
-
Bern、スイス
- 募集
- Inselspital Bern
-
コンタクト:
- Sabine Schmid
- メール:sabine.schmid@insel.ch
-
Fribourg、スイス
- 募集
- HFR Hôpital Fribourgeois
-
コンタクト:
- Adrienne Bettini
- メール:Adrienne.Bettini@h-fr.ch
-
Lausanne、スイス
- まだ募集していません
- CHUV
-
コンタクト:
- Hasna Bouchaab
- メール:hasna.bouchaab@chuv.ch
-
Sankt Gallen、スイス
- 募集
- Kantonsspital St.Gallen
-
コンタクト:
- Martin Früh
- メール:Martin.frueh@kssg.ch
-
Winterthur、スイス
- 募集
- Kantonsspital Winterthur
-
コンタクト:
- Laetitia Mauti
- メール:laetitia.mauti@ksw.ch
-
Zurich、スイス
- まだ募集していません
- University Hospital Zurich
-
コンタクト:
- Isabelle Opitz
- メール:isabelle.schmitt-opitz@usz.ch
-
-
-
-
-
Angers、フランス
- 募集
- CHU Angers
-
コンタクト:
- Youssef Oulkhouir
- メール:Youssef.Oulkhouir@chu-angers.fr
-
Bordeaux、フランス
- 募集
- Institut Bergonié
-
コンタクト:
- Sophie Cousin
- メール:s.cousin@bordeaux.unicancer.fr
-
Le Mans、フランス
- 募集
- Le Mans - CHG
-
コンタクト:
- Camille Guguen
- メール:cguguen@ch-lemans.fr
-
Lyon、フランス
- 募集
- Lyon - Centre Léon Bérard
-
コンタクト:
- Maurice Pérol
- メール:maurice.perol@lyon.unicancer.fr
-
-
-
-
-
Anderlecht、ベルギー
- 募集
- Institut Jules Bordet - HUB
-
コンタクト:
- Mariana Brandao
- メール:mariana.brandao@hubruxelles.be
-
Antwerp、ベルギー
- 募集
- Antwerp University Hospital
-
コンタクト:
- Reinier Wener
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria for enrolment:
- Histologically confirmed NSCLC.
- Stage IIB-IIIB (T1-4 N0-2) according to 8th edition of the TNM staging system of lung cancer.
Stage III assessment should include samples of lymph nodes at levels 4, bilaterally, and level 7 to rule out stage IIIB N3 disease.
T4 tumours will only be eligible if they are defined as T4 based only on their size (>7cm); any other reason will be considered ineligible.
- Known PD-L1 status, as tested locally using a validated assay. To ensure comparability of results, it is strongly encouraged that PD-L1 testing is done with the Ventana PD-L1 (SP263) assay.
- Absence of EGFR mutation or ALK translocation, as tested locally.
- Primary tumour resectable and functionally operable as assessed per local multidisciplinary tumour board (cardiac evaluation, pulmonary function and diffusion capacity, comorbidity).
- Adequate haematological function:
Haemoglobin ≥90 g/L, Absolute neutrophil count (ANC) ≥1.0× 109/L, Platelet count ≥75× 109/L.
- Adequate renal function: Measured creatinine clearance (CL) >40 mL/min or calculated CL >40 mL/min calculated by the Cockcroft-Gault.
- Adequate liver function: ALT and AST ≤2.5× institutional ULN, Total serum bilirubin ≤1.5× institutional ULN (patients with Gilbert's syndrome may be allowed to be enrolled after consultation with the Medical Affairs Team at the ETOP IBCSG Partners Foundation.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Age ≥18 at the time of enrolment.
- Body weight >30 kg.
- Life expectancy of at least 12 weeks.
- Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative urinary or serum pregnancy test at screening before enrolment. Pregnancy test must be repeated within 3 days before the first dose of protocol treatment.
- Written IC for study participation must be signed and dated by the patient and the investigator prior to any study-related intervention.
Eligibility Criteria for randomisation:
- Surgical resection must have been completed. Note: Participants who have had only had segmentectomy or wedge resections are not eligible for randomisation.
- Patients must have complete resection: R0 or R1 resection.
- Patients must be fit to receive adjuvant treatment with durvalumab.
- Patients must have no evidence of metastatic disease as assessed by CT scan.
- Documentation of pathological response as per local review must be available.
Exclusion Criteria for enrolment:
- T4 with invasion of heart, great vessels, carina, trachea, oesophagus, or spine.
- Any previous or concurrent treatments for NSCLC.
- Any previous immunotherapy.
- Major surgical procedure (as per investigators assessment) within 28 days before enrolment.
- History of allogenic organ transplantation.
- Active or prior documented autoimmune disease or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.]). The following are exceptions to this criterion:
Patients with vitiligo or alopecia. Patients with type I diabetes. Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement.
Any chronic skin condition that does not require systemic therapy. Patients without active disease in the last 5 years may be included but only after consultation with the Medical Affairs Team at the ETOP IBCSG Partners Foundation.
Patients with celiac disease controlled by diet alone.
- Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease (ILD), or serious chronic gastrointestinal conditions associated with diarrhoea.
- Psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.
- History of another primary malignancy except for:
Malignancy treated with curative-intent and with no known active disease 5 years before the first dose of durvalumab and of low potential risk for recurrence.
Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
Adequately treated carcinoma in situ without evidence of disease.
- History of leptomeningeal carcinomatosis.
- History of active primary immunodeficiency.
- Active hepatitis infection, positive hepatitis C virus (HCV) antibody, hepatitis B virus (HBV) surface antigen (HbsAg) or HBV core antibody (anti-HBc).
Participants with a past or resolved HBV infection (defined as the presence of anti-HBc and absence of HbsAg) are eligible.
Participants positive for HCV antibody are only eligible if polymerase chain reaction is negative for HCV RNA.
- Known HIV infection that is not well-controlled. All of the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA load for 3 months, CD4+ count of 500 cell per mm3, no history of AIDS-defining opportunistic infection within the past 12 months, and stable for at least 3 months on the same anti-HIV medication.
- Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:
Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection).
Systemic corticosteroids at physiologic doses not exceeding 10 mg/day of prednisone or its equivalent.
Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
- Receipt of live attenuated vaccine within 30 days prior to the first dose of durvalumab.
Note: Patients in the ADOPT-lung trial, should not receive live vaccine whilst receiving durvalumab and for up to 30 days after the last dose.
Concurrent enrolment in another interventional clinical trial.
- Known allergy or suspected hypersensitivity to durvalumab or its excipients.
- Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
- Female patients who are pregnant or in the period of lactation.
- Female patients of childbearing potential and sexually active men who are not willing to use a highly effective contraceptive method during the trial until at least 90 days after the last dose of protocol treatment.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Durvalumab
Protocol treatment in the adjuvant phase consists of adjuvant durvalumab |
Durvalumab is given at a fixed dose of 1500 mg i.v. every 4 weeks (±1 week) until relapse or unacceptable toxicity, for a maximum of 12 cycles after surgery. |
|
介入なし:Observation
Observation only |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Disease-free survival (DFS)
時間枠:From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Assessed in the adjuvant treatment phase. DFS is defined as the time from the date of randomisation until disease recurrence (including loco-regional recurrence, a distant (metastatic) recurrence or a second primary) or death from any cause. Censoring (for patients without recurrence/death) will occur at the date of last tumour assessment. Patients without a post-randomisation tumour assessment will be censored at the date of randomisation (plus 1 day). DFS will be assessed in patients without pCR (primary endpoint), as well as in patients with pCR (secondary endpoint) and in patients with/without ctDNA clearance (secondary endpoints). |
From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
DFS in patients with pCR
時間枠:From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Assessed in the adjuvant treatment phase (after randomisation). DFS is defined as the time from the date of randomisation until disease recurrence (including loco-regional recurrence, a distant (metastatic) recurrence or a second primary) or death from any cause. Censoring (for patients without recurrence/death) will occur at the date of last tumour assessment. Patients without a post-randomisation tumour assessment will be censored at the date of randomisation (plus 1 day). DFS will be assessed in patients without pCR (primary endpoint), as well as in patients with pCR (secondary endpoint) and in patients with/without ctDNA clearance (secondary endpoints). |
From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
|
Overall survival (OS) in patients with/without pCR
時間枠:From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Assessed in the adjuvant treatment phase (after randomisation). OS is defined as the time from the date of randomisation until death from any cause. Censoring (for patients who are not reported as having died) will occur at the date when they were last known to be alive. Patients without post-randomisation information will be censored at the date of randomisation (plus 1 day). OS will be assessed in patients with/without pCR. |
From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
|
DFS in patients with/without ctDNA clearance
時間枠:From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Assessed in the adjuvant treatment phase (after randomisation). |
From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
|
Time to recurrence (TTR) in patients with/without pCR
時間枠:From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Assessed in the adjuvant treatment phase (after randomisation). TTR is defined as the time from the date of randomisation until disease recurrence. Censoring (for patients without recurrence) will occur at the date of the last tumour assessment. Patients without a post-randomisation tumour assessment will be censored at the date of randomisation (plus 1 day). TTR will be assessed in patients with/without pCR. |
From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
|
Time to treatment discontinuation (TTD) in patients with/without pCR
時間枠:From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Assessed in the adjuvant treatment phase (after randomisation). |
From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
|
Toxicity according to CTCAE v5.0
時間枠:From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Assessed in the adjuvant treatment phase (after randomisation). All safety parameters will be summarised in tables to evaluate the toxicity/safety profile of the protocol treatment based on:
|
From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Correlation between ctDNA clearance and DFS
時間枠:From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Exploratory endpoint |
From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
|
Correlation between ctDNA clearance and OS
時間枠:From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Exploratory endpoint |
From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
|
Correlation between ctDNA clearance and initial PD-L1 assessment
時間枠:From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Exploratory endpoint |
From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
|
Outcome (event-free survival)
時間枠:From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Outcome (EFS) in patients with patients with either
|
From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
|
Correlation of Outcome Disease-free survival (DFS)
時間枠:From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Correlation of Outcome (DFS) in patients with longitudinal ctDNA assessment |
From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
|
Correlation of Outcome Overall survival (OS)
時間枠:From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
Correlation of Outcome (OS) in patients with longitudinal ctDNA assessment |
From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
|
pCRDescription of patients entering each phase (e.g., % surgery, % randomised)
時間枠:From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
pCRDescription of patients entering each phase (e.g., % surgery, % randomised) |
From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
|
協力者と研究者
協力者
捜査官
- スタディチェア:Solange Peters, MD-PhD、Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland
- スタディチェア:Sabine Schmid, MD、Inselspital, Universitätsspital Bern, 3010 Bern, Switzerland
- スタディチェア:Paul Van Schil, MD-PhD、Antwerp University Hospital, Antwerp, Belgium,
- スタディチェア:Stephen Finn, MD-PhD、St. James's Hospital, Dublin 8, Ireland
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。